PALIO and GSW to Operate as Singular Advertising Powerhouse Under GSW Brand
GSW and PALIO have collectively worked on more than 75 global brand launches, including 12 blockbuster launches across 12 different therapeutic categories. Their client rosters include large biopharma and med tech organizations tapping specialized services, and emerging companies who require a full suite of strategic, creative and digital solutions.
“Unprecedented changes in the healthcare market require constant evolution to continuously bring customers unparalleled strategic and creative solutions,” said Foster-Storch. “Bringing together PALIO and GSW under one brand creates an advertising powerhouse, fueled by incredible talent, insights and the resources required to meet our customers’ dynamic needs.”
“Michael Austin and
GSW, founded in 1977, is a full-service healthcare advertising agency that creates personalized brand experiences to involve, inspire, educate and activate people through ongoing brand journeys. Their “Speak People” philosophy – using insights to connect with consumers simply and authentically – has led GSW to being one of the top-ten awarded ad agencies in the industry.
PALIO, founded in 1999, is a health and wellness advertising agency committed to brilliant ideas, strategic excellence and the art of storytelling. Touting “Pacific thinking informed by
The expanded GSW agency is part of
Cautionary Statement Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of our business with the business of inVentiv, and our operation of the combined business following the closing of the Merger; our ability to maintain or generate new business awards; our ability to increase our market share, grow our business, and execute our growth strategies; our backlog not being indicative of future revenues and our ability to realize the anticipated future revenue reflected in our backlog; our ability to adequately price our contracts and not overrun cost estimates; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in our financial results; reliance on key personnel; our customer or therapeutic area concentration; and the other risk factors set forth in our Form-Q for the quarter ended
Vice President, Investor Relations
+1 919 745 2745
+1 202 210 5992
Source: Syneos Health